NVCR NovoCure Limited Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

NVCR [NASD]

NovoCure Limited

Healthcare | Medical Appliances & Equipment | USA

financial highlights | statements

Index	-	P/E	-	EPS (ttm)	-0.69	Insider Own	1.80%	Shs Outstand	100.97M	Perf Week	-8.61%
Market Cap	4.75B	Forward P/E	106.19	EPS next Y	0.44	Insider Trans	-49.06%	Shs Float	75.94M	Perf Month	-11.88%
Income	-63.60M	PEG	-	EPS next Q	-0.14	Inst Own	71.60%	Short Float	5.10%	Perf Quarter	45.91%
Sales	248.10M	P/S	19.14	EPS this Y	36.50%	Inst Trans	10.47%	Short Ratio	5.07	Perf Half Y	-9.54%
Book/sh	1.21	P/B	38.88	EPS next Y	178.00%	ROA	-20.00%	Target Price	58.00	Perf Year	107.68%
Cash/sh	2.44	P/C	19.32	EPS next 5Y	-	ROE	-57.10%	52W Range	19.55 - 56.67	Perf YTD	40.50%
Dividend	-	P/FCF	-	EPS past 5Y	5.90%	ROI	-19.60%	52W High	-16.99%	Beta	3.17
Dividend %	-	Quick Ratio	4.60	Sales past 5Y	88.70%	Gross Margin	67.70%	52W Low	140.61%	ATR	1.92
Employees	598	Current Ratio	5.00	Sales Q/Q	29.80%	Oper. Margin	-13.60%	RSI (14)	35.63	Volatility	4.44% 4.05%
Optionable	Yes	Debt/Eq	1.33	EPS Q/Q	67.20%	Profit Margin	-25.60%	Rel Volume	0.71	Prev Close	50.00
Shortable	Yes	LT Debt/Eq	1.33	Earnings	Feb 28 BMO	Payout	-	Avg Volume	764.00K	Price	47.04
Recom	2.00	SMA20	-8.65%	SMA50	-5.23%	SMA200	16.77%	Volume	541,228	Change	-5.92%

Mar-20-19

Initiated

SunTrust

Hold

Nov-02-18

Downgrade

Wells Fargo

Outperform → Market Perform

Jul-16-18

Initiated

Evercore ISI

Outperform

$46

Apr-18-18

Reiterated

Mizuho

Buy

$28 → $32

Feb-23-18

Reiterated

Mizuho

Buy

$25 → $28

May-24-17

Upgrade

Wells Fargo

Market Perform → Outperform

Jul-29-16

Reiterated

Wedbush

Outperform

$30 → $20

Jan-19-16

Initiated

Barclays

Underweight

$16

Dec-02-15

Initiated

Deutsche Bank

Hold

$28

Oct-27-15

Initiated

Wedbush

Outperform

Oct-27-15

Initiated

JP Morgan

Overweight

Oct-27-15

Initiated

JMP Securities

Mkt Outperform

$43

Mar-22-19 07:30AM	Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer Business Wire -5.92%
Mar-21-19 07:30AM	Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019 Business Wire
06:52AM	Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role MarketWatch
06:30AM	Novocures Chief Science Officer Retires after 17 Years of Service Business Wire
Mar-18-19 07:30AM	Novocure to Participate in Oppenheimers 29th Annual Healthcare Conference Business Wire
Mar-12-19 09:37AM	Does NovoCure Limiteds (NASDAQ:NVCR) Past Performance Indicate A Weaker Future? Simply Wall St.
Mar-08-19 08:45AM	Options Traders Expect Huge Moves in NovoCure (NVCR) Stock Zacks
Mar-04-19 11:58PM	Edited Transcript of NVCR earnings conference call or presentation 28-Feb-19 1:00pm GMT Thomson Reuters StreetEvents -5.83%
06:15PM	Novocure Ltd (NVCR) CEO Asaf Danziger Sold $5.6 million of Shares GuruFocus.com
Feb-28-19 03:21PM	NovoCure (NVCR) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:00AM	Novocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update Business Wire
Feb-21-19 11:49AM	3 Medical Device Companies for Your Watchlist Motley Fool
Jan-23-19 11:38AM	How Many Insiders Sold NovoCure Limited (NASDAQ:NVCR) Shares? Simply Wall St.
Jan-18-19 06:15PM	Novocure Ltd (NVCR) CEO Asaf Danziger Sold $9 million of Shares GuruFocus.com
Jan-16-19 06:15PM	Novocure Ltd (NVCR) CEO Asaf Danziger Sold $8.7 million of Shares GuruFocus.com
Jan-11-19 12:24PM	Tamarack Capital Managements Return, AUM, and Holdings Insider Monkey
Jan-07-19 04:05PM	Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update Business Wire
Dec-27-18 09:23AM	Stocks down in December for pharma firms in the Triangle American City Business Journals
Dec-24-18 09:44AM	Is NovoCure a Buy? Motley Fool
Dec-21-18 07:30AM	Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-17-18 02:20PM	What Kind Of Shareholder Owns Most NovoCure Limited (NASDAQ:NVCR) Stock? Simply Wall St.
07:30AM	Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields Business Wire
Dec-16-18 09:10AM	Is NovoCure Limited (NVCR) A Good Stock To Buy? Insider Monkey
Dec-12-18 11:49AM	3 Top Medical Device Stocks to Buy Now Motley Fool
Dec-07-18 07:55AM	Recent Analysis Shows Moody's, Hershey, NovoCure, Mohawk Industries, La-Z-Boy, and Lockheed Martin Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Dec-06-18 07:30AM	Sub-Group Analysis of Novocures EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival Business Wire
Nov-14-18 07:30AM	Zai Lab and Novocure Awarded Deal of the Year GlobeNewswire
07:30AM	Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China Business Wire
Nov-13-18 08:01PM	3 Top Healthcare Stocks to Buy in November Motley Fool
08:24AM	Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology Business Wire
Nov-07-18 04:00PM	Novocure and Zai Lab to Host Investor Event Business Wire +8.33%
12:25PM	NovoCure Limited (NASDAQ:NVCR): Is Breakeven Near? Simply Wall St.
11:22AM	Here's Why NovoCure Fell 36.8% in October Motley Fool
Oct-30-18 02:04PM	Edited Transcript of NVCR earnings conference call or presentation 25-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
07:30AM	New Research Coverage Highlights HomeStreet, Cousins Properties, Carbo Ceramics, Cowen Group, CTS, and NovoCure Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-25-18 03:11PM	Here's Why Novocure Is Tumbling Today Motley Fool -18.98%
09:05AM	NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates Zacks
06:00AM	Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update Business Wire
Oct-24-18 04:00PM	Novocure Founder Professor Yoram Palti and Director Louis J. Lavigne, Jr. Retire from Board of Directors Business Wire
Oct-23-18 05:57PM	Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma Business Wire
Oct-22-18 07:30AM	Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields Business Wire
Oct-18-18 10:33AM	NovoCure (NVCR) Q3 Earnings Preview: What to Look Out For Zacks
07:30AM	Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune® Business Wire
Oct-11-18 08:03AM	Why Novocure Stock Jumped 16.3% in September Motley Fool
Oct-04-18 09:08AM	Novocure Announces 55 Presentations at European Association of Neuro-Oncology Meeting 2018 Business Wire
Oct-02-18 11:51AM	3 Medical Devices Stocks to Buy InvestorPlace
Oct-01-18 08:36AM	Novocure to Report Third Quarter 2018 Financial Results Business Wire
Sep-25-18 07:30AM	Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer Business Wire
Sep-14-18 03:04PM	What Investors Should Know About NovoCure Limiteds (NASDAQ:NVCR) Financial Strength Simply Wall St.
Sep-13-18 10:57AM	5 Medical Device Stocks With Impressive Staying Power InvestorPlace
Sep-12-18 07:30AM	Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China Business Wire
Sep-10-18 10:31AM	Why Novocure Gained 33% in August Motley Fool
Sep-06-18 11:24AM	Stocks - Cloudera, Verint Systems, Novocure Soar in Pre-market; Lands' End Tumbles Investing.com +5.34%
08:00AM	Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and NovoCure ACCESSWIRE
Sep-05-18 05:00PM	Tumor Treating Fields Plus Standard of Care Chemotherapy Significantly Extends Median Overall Survival by 6.1 Months in STELLAR Phase 2 Registration Trial in Mesothelioma Compared to Historical Control Business Wire
Aug-31-18 04:38PM	This brain cancer drug stock has been on a tear Yahoo Finance
Aug-26-18 07:15PM	3 Small-Cap Healthcare Stocks for Your Watch List Motley Fool
Aug-24-18 08:00AM	Today's Research Reports on Trending Tickers: Exact Sciences and NovoCure ACCESSWIRE
Aug-23-18 07:55AM	Research Report Identifies Genesis Healthcare, Maiden, Ichor, Armstrong World Industries, Rexnord, and NovoCure with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-17-18 07:30AM	This $7 Biotech Stock Could Be Worth $20 or More After Recent Developments ACCESSWIRE
Aug-15-18 08:38AM	Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:30AM	Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer Business Wire
Aug-06-18 12:18PM	Forget Bitcoin: You're Better Off Buying These 3 Stocks Motley Fool
Aug-03-18 07:30AM	Novocure to Present at Two Upcoming Investor Conferences Business Wire
Aug-02-18 07:30AM	Novocure Announces Addition to Its Board of Directors Business Wire
Jul-31-18 07:30AM	Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer Business Wire
Jul-26-18 07:19PM	Edited Transcript of NVCR earnings conference call or presentation 26-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
06:00AM	Novocure Reports Second Quarter 2018 Financial Results and Provides Company Update Business Wire
Jul-19-18 07:30AM	Novocure Announces 13 Presentations at American Society for Radiation Oncology 2018 Annual Meeting Business Wire
Jul-17-18 08:54AM	NovoCure (NVCR) Catches Eye: Stock Jumps 7.4% Zacks
07:30AM	Scientific Track Dedicated to Tumor Treating Fields at 40th International Conference of the IEEE Engineering in Medicine and Biology Society Business Wire
Jul-16-18 07:05AM	Free Pre-Market Technical Recap on Nevro and Three Additional Medical Equipment Stocks ACCESSWIRE +7.40%
Jul-14-18 03:35PM	Here's Why Novocure Ltd. Rose 55% in the First Half of 2018 Motley Fool
Jul-06-18 09:13AM	Trade of the Day: Novocure Ltd (NVCR) InvestorPlace
Jul-02-18 08:00AM	Novocure Appoints Pritesh Shah as Chief Commercial Officer Business Wire
07:30AM	Novocure to Report Second Quarter 2018 Financial Results Business Wire
Jun-21-18 02:40PM	NovoCure's Charts Look Bullish TheStreet.com
Jun-20-18 07:01PM	Cramer's lightning round: The pecking order for my favori... CNBC Videos
06:49PM	Cramer's lightning round: The pecking order for my favorite cybersecurity stocks CNBC
Jun-15-18 08:10AM	Investor Expectations to Drive Momentum within NovoCure, Canada Goose, Telephone and Data, FMC, MobileIron, and Viking Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Jun-04-18 10:37AM	The Probable Reason Behind NovoCure's Double-Digit Drop Today Motley Fool -7.51%
07:30AM	Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018 Business Wire
May-31-18 04:05PM	Novocure Announces Changes to Its Board of Directors Business Wire
07:20AM	Breakfast Technical Briefing on NovoCure and Three Other Additional Medical Equipment Stocks ACCESSWIRE
May-14-18 12:02PM	Best Growth Stock in May Simply Wall St.
May-11-18 11:46AM	Edited Transcript of NVCR earnings conference call or presentation 26-Apr-18 12:00pm GMT Thomson Reuters StreetEvents
Apr-26-18 04:53PM	This Explains Why NovoCure Is Surging Today Motley Fool +9.73%
11:55AM	NovoCure: 1Q Earnings Snapshot Associated Press
06:00AM	Novocure Reports First Quarter 2018 Financial Results and Provides Company Update Business Wire
06:00AM	Novocure Ltd. to Host Earnings Call ACCESSWIRE
Apr-25-18 11:10AM	NovoCure (NVCR) Shares March Higher, Can It Continue Zacks
Apr-19-18 08:00AM	Analysis: Positioning to Benefit within Verastem, DineEquity, Olin, Quantum, Kimco Realty, and NovoCure Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.04%
07:10AM	Blog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in Mesothelioma ACCESSWIRE
Apr-18-18 08:31AM	NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session Zacks
Apr-17-18 07:30AM	Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma Business Wire +7.89%
Apr-13-18 06:31PM	3 Top Healthcare Stocks to Buy in April Motley Fool
04:30PM	Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting Business Wire
Apr-03-18 12:23PM	Is NovoCure Limiteds (NASDAQ:NVCR) Balance Sheet A Threat To Its Future? Simply Wall St.
07:30AM	Novocure to Report First Quarter 2018 Financial Results Business Wire
Mar-20-18 09:14AM	NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma Business Wire

Markets a wearable electric field device for treating glioblastoma brain cancer.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEUNG GABRIEL	Director	Mar 11	Option Exercise	3.44	5,000	17,200	65,000	Mar 12 04:56 PM
LEUNG GABRIEL	Director	Mar 11	Sale	48.31	5,000	241,550	60,000	Mar 12 04:56 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Mar 05	Option Exercise	3.44	31,234	107,445	97,498	Mar 06 04:18 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Mar 05	Sale	53.40	31,234	1,668,021	66,264	Mar 06 04:18 PM
Danziger Asaf	Chief Executive Officer	Mar 04	Option Exercise	14.37	16,268	233,771	250,025	Mar 06 04:17 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Mar 04	Option Exercise	3.44	58,766	202,155	106,264	Mar 06 04:18 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Mar 04	Sale	54.22	58,766	3,186,291	66,264	Mar 06 04:18 PM
Danziger Asaf	Chief Executive Officer	Mar 04	Sale	55.89	16,268	909,286	233,757	Mar 06 04:17 PM
Shah Pritesh	Chief Commercial Officer	Mar 01	Option Exercise	13.77	40,586	558,810	42,136	Mar 04 04:13 PM
Danziger Asaf	Chief Executive Officer	Mar 01	Option Exercise	14.37	100,000	1,437,000	333,757	Mar 04 04:15 PM
LEUNG GABRIEL	Director	Mar 01	Option Exercise	3.44	25,000	86,000	85,000	Mar 04 04:14 PM
Shah Pritesh	Chief Commercial Officer	Mar 01	Sale	55.63	40,586	2,257,697	25,239	Mar 04 04:13 PM
Danziger Asaf	Chief Executive Officer	Mar 01	Sale	55.57	100,000	5,556,582	233,757	Mar 04 04:15 PM
LEUNG GABRIEL	Director	Mar 01	Sale	55.01	25,000	1,375,275	60,000	Mar 04 04:14 PM
Danziger Asaf	Chief Executive Officer	Feb 28	Option Exercise	14.37	903	12,976	234,660	Mar 01 04:31 PM
Longsworth Todd Christopher	General Counsel	Feb 28	Sale	53.68	2,368	127,114	36,835	Mar 01 04:30 PM
Shah Pritesh	Chief Commercial Officer	Feb 28	Sale	53.68	1,558	83,633	25,239	Mar 01 04:32 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 28	Sale	53.68	3,288	176,500	66,264	Mar 01 04:36 PM
Danziger Asaf	Chief Executive Officer	Feb 28	Sale	54.40	903	49,119	233,757	Mar 01 04:31 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 28	Sale	53.68	2,397	128,671	169,305	Mar 01 04:35 PM
DOYLE WILLIAM F	Executive Chairman	Feb 28	Sale	53.68	3,097	166,247	918,306	Mar 01 04:52 PM
DOYLE WILLIAM F	Executive Chairman	Feb 27	Option Exercise	52.90	9,260	489,854	921,403	Mar 01 04:52 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 27	Option Exercise	52.90	6,174	326,605	171,702	Mar 01 04:35 PM
Kirson Eilon D.	Chief Science Officer	Feb 27	Option Exercise	52.90	6,945	367,391	152,408	Mar 01 04:34 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 27	Option Exercise	52.90	7,717	408,229	69,552	Mar 01 04:36 PM
Danziger Asaf	Chief Executive Officer	Feb 27	Option Exercise	52.90	9,260	489,854	233,757	Mar 01 04:31 PM
Shah Pritesh	Chief Commercial Officer	Feb 27	Option Exercise	52.90	3,087	163,302	26,797	Mar 01 04:32 PM
Longsworth Todd Christopher	General Counsel	Feb 27	Option Exercise	52.90	5,556	293,912	39,203	Mar 01 04:30 PM
Longsworth Todd Christopher	General Counsel	Feb 25	Sale	53.63	9,325	500,081	33,647	Feb 26 05:54 PM
Shah Pritesh	Chief Commercial Officer	Feb 25	Sale	53.63	6,377	341,986	23,710	Feb 26 05:56 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 25	Sale	53.63	18,647	1,000,001	61,835	Feb 26 05:58 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 25	Sale	53.63	12,230	655,870	165,528	Feb 26 06:00 PM
Longsworth Todd Christopher	General Counsel	Feb 22	Option Exercise	53.38	21,667	1,156,584	42,972	Feb 26 05:54 PM
Danziger Asaf	Chief Executive Officer	Feb 22	Option Exercise	53.38	53,333	2,846,916	224,497	Feb 26 05:51 PM
Shah Pritesh	Chief Commercial Officer	Feb 22	Option Exercise	53.38	13,000	693,940	30,087	Feb 26 05:56 PM
Kirson Eilon D.	Chief Science Officer	Feb 22	Option Exercise	53.38	36,400	1,943,032	145,463	Feb 26 05:57 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Feb 22	Option Exercise	53.38	43,333	2,313,116	80,482	Feb 26 05:58 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 22	Option Exercise	53.38	31,200	1,665,456	177,758	Feb 26 06:00 PM
LEUNG GABRIEL	Director	Feb 11	Option Exercise	3.44	5,000	17,200	65,000	Feb 13 04:08 PM
LEUNG GABRIEL	Director	Feb 11	Sale	49.59	5,000	247,950	60,000	Feb 13 04:08 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 04	Option Exercise	7.15	21,000	150,150	167,558	Feb 05 04:16 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 04	Sale	49.53	21,000	1,040,193	146,558	Feb 05 04:16 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 01	Option Exercise	7.15	37,500	268,125	184,058	Feb 05 04:16 PM
Ambrogi Michael J.	Chief Operating Officer	Feb 01	Sale	49.03	37,500	1,838,654	146,558	Feb 05 04:16 PM
Longsworth Todd Christopher	General Counsel	Jan 25	Option Exercise	7.15	11,874	84,899	33,179	Jan 28 04:15 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 25	Option Exercise	3.44	35,000	120,400	72,149	Jan 28 04:12 PM
LEUNG GABRIEL	Director	Jan 25	Option Exercise	3.44	20,000	68,800	80,000	Jan 28 04:13 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 25	Sale	49.20	35,000	1,722,000	37,149	Jan 28 04:12 PM
Longsworth Todd Christopher	General Counsel	Jan 25	Sale	50.15	11,874	595,481	21,305	Jan 28 04:15 PM
LEUNG GABRIEL	Director	Jan 25	Sale	50.00	20,000	1,000,000	60,000	Jan 28 04:13 PM
Longsworth Todd Christopher	General Counsel	Jan 24	Option Exercise	7.15	15,000	107,250	36,305	Jan 28 04:15 PM
Longsworth Todd Christopher	General Counsel	Jan 24	Sale	48.15	15,000	722,250	21,305	Jan 28 04:15 PM
Danziger Asaf	Chief Executive Officer	Jan 23	Option Exercise	7.48	88,695	663,439	259,859	Jan 25 04:10 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 23	Option Exercise	3.44	35,000	120,400	72,149	Jan 25 04:12 PM
Danziger Asaf	Chief Executive Officer	Jan 23	Sale	47.48	88,695	4,211,239	171,164	Jan 25 04:10 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 23	Sale	47.35	35,000	1,657,250	37,149	Jan 25 04:12 PM
Danziger Asaf	Chief Executive Officer	Jan 18	Option Exercise	3.44	46,863	161,209	218,027	Jan 22 05:13 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 18	Option Exercise	3.44	30,000	103,200	67,149	Jan 22 05:14 PM
Danziger Asaf	Chief Executive Officer	Jan 18	Sale	45.91	46,863	2,151,356	171,164	Jan 22 05:13 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 18	Sale	45.90	30,000	1,376,910	37,149	Jan 22 05:14 PM
Kirson Eilon D.	Chief Science Officer	Jan 17	Option Exercise	14.37	68,813	988,843	177,876	Jan 18 04:13 PM
Danziger Asaf	Chief Executive Officer	Jan 17	Option Exercise	3.44	100,000	344,000	271,164	Jan 18 04:15 PM
Kirson Eilon D.	Chief Science Officer	Jan 17	Sale	45.25	68,813	3,113,788	109,063	Jan 18 04:13 PM
Danziger Asaf	Chief Executive Officer	Jan 17	Sale	45.26	100,000	4,526,400	171,164	Jan 18 04:15 PM
Longsworth Todd Christopher	General Counsel	Jan 16	Option Exercise	7.15	15,000	107,250	36,305	Jan 18 04:12 PM
Kirson Eilon D.	Chief Science Officer	Jan 16	Option Exercise	14.37	100,000	1,437,000	209,063	Jan 18 04:13 PM
Danziger Asaf	Chief Executive Officer	Jan 16	Option Exercise	3.44	100,000	344,000	271,164	Jan 18 04:15 PM
Shah Pritesh	Chief Commercial Officer	Jan 16	Option Exercise	15.55	25,000	388,750	29,587	Jan 18 04:17 PM
LEUNG GABRIEL	Director	Jan 16	Option Exercise	3.44	20,000	68,800	80,000	Jan 18 04:19 PM
Longsworth Todd Christopher	General Counsel	Jan 16	Sale	45.15	15,000	677,250	21,305	Jan 18 04:12 PM
Kirson Eilon D.	Chief Science Officer	Jan 16	Sale	45.11	100,000	4,511,000	109,063	Jan 18 04:13 PM
Danziger Asaf	Chief Executive Officer	Jan 16	Sale	45.05	100,000	4,505,304	171,164	Jan 18 04:15 PM
Shah Pritesh	Chief Commercial Officer	Jan 16	Sale	45.00	25,000	1,125,075	17,087	Jan 18 04:17 PM
LEUNG GABRIEL	Director	Jan 16	Sale	45.00	20,000	900,060	60,000	Jan 18 04:19 PM
Danziger Asaf	Chief Executive Officer	Jan 15	Option Exercise	3.44	100,000	344,000	271,164	Jan 16 04:31 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 15	Option Exercise	3.44	30,000	103,200	67,149	Jan 16 04:32 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 15	Sale	44.20	30,000	1,326,000	37,149	Jan 16 04:32 PM
Danziger Asaf	Chief Executive Officer	Jan 15	Sale	43.49	100,000	4,348,800	171,164	Jan 16 04:31 PM
Danziger Asaf	Chief Executive Officer	Jan 14	Option Exercise	3.44	100,000	344,000	271,164	Jan 16 04:31 PM
Danziger Asaf	Chief Executive Officer	Jan 14	Sale	43.52	100,000	4,352,400	171,164	Jan 16 04:31 PM
Shah Pritesh	Chief Commercial Officer	Jan 11	Option Exercise	12.43	26,251	326,302	34,587	Jan 14 04:35 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 11	Option Exercise	3.44	30,000	103,200	67,149	Jan 14 04:30 PM
GROENHUYSEN WILHELMUS CM	Chief Financial Officer	Jan 11	Sale	42.35	30,000	1,270,500	37,149	Jan 14 04:30 PM
Shah Pritesh	Chief Commercial Officer	Jan 11	Sale	42.00	26,251	1,102,647	17,087	Jan 14 04:35 PM
LEUNG GABRIEL	Director	Jan 10	Option Exercise	3.44	5,000	17,200	65,000	Jan 14 04:32 PM
Ambrogi Michael J.	Chief Operating Officer	Jan 10	Option Exercise	14.37	54,930	789,344	201,488	Jan 14 04:34 PM
LEUNG GABRIEL	Director	Jan 10	Sale	39.91	5,000	199,550	60,000	Jan 14 04:32 PM
Ambrogi Michael J.	Chief Operating Officer	Jan 10	Sale	40.88	54,930	2,245,810	146,558	Jan 14 04:34 PM
LEUNG GABRIEL	Director	Jan 09	Option Exercise	3.44	20,000	68,800	80,000	Jan 11 04:23 PM
Shah Pritesh	Chief Commercial Officer	Jan 09	Option Exercise	14.37	8,988	129,158	26,075	Jan 11 04:16 PM
Ambrogi Michael J.	Chief Operating Officer	Jan 09	Option Exercise	13.64	100,000	1,364,250	221,558	Jan 11 04:18 PM
Longsworth Todd Christopher	General Counsel	Jan 09	Option Exercise	7.15	15,000	107,250	36,305	Jan 11 04:21 PM
Ambrogi Michael J.	Chief Operating Officer	Jan 09	Sale	40.00	100,000	4,000,000	146,558	Jan 11 04:18 PM
Shah Pritesh	Chief Commercial Officer	Jan 09	Sale	40.00	8,988	359,550	17,087	Jan 11 04:16 PM
LEUNG GABRIEL	Director	Jan 09	Sale	40.00	20,000	800,067	60,000	Jan 11 04:23 PM
Longsworth Todd Christopher	General Counsel	Jan 09	Sale	40.15	15,000	602,250	21,305	Jan 11 04:21 PM
Shah Pritesh	Chief Commercial Officer	Dec 12	Option Exercise	7.34	38,781	284,720	39,619	Dec 13 05:27 PM
Shah Pritesh	Chief Commercial Officer	Dec 12	Sale	36.00	38,781	1,396,136	17,087	Dec 13 05:27 PM
LEUNG GABRIEL	Director	Dec 10	Option Exercise	3.44	5,000	17,200	65,000	Dec 12 04:26 PM
LEUNG GABRIEL	Director	Dec 10	Sale	33.49	5,000	167,450	60,000	Dec 12 04:26 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience